[Edaily Reporter Hyera Lee ]Hironic Co.,Ltd(149980)announced on the 20th that it will pay a quarterly dividend for the first time since its founding.

Hironic Co.,Ltd held a board of directors meeting on the 16th and resolved to pay a cash dividend of 233 won per common share for the second quarter of this year. The total dividend amount is approximately 4 billion won.
Since trading resumed, Hironic Co.,Ltd has canceled all of its treasury shares through a profit-based cancellation. Following efforts to enhance per-share value by reducing the number of outstanding shares, the company has expanded its shareholder return policy by distributing cash through this first-ever quarterly dividend.
Alongside shareholder returns, the company is also pursuing the expansion of its new product portfolio. This month, the multi-functional medical device “SYNERJET PRO” and the microwave medical device “MIGLOU” received product approvals from the Ministry of Food and Drug Safety.
In overseas markets, the “New Double-Lo Series” received certification from Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS) and Colombia’s National Institute for Food and Medicines Surveillance (INVIMA), establishing a sales network across three Latin American countries, including Brazil’s National Health Surveillance Agency (ANVISA). “Synerget” has received approval from the Taiwan Food and Drug Administration (TFDA) and has begun shipping; it is currently undergoing the U.S. Food and Drug Administration (FDA) 510(k) certification process.
In addition, Hironic Co.,Ltd. is continuing to expand into overseas markets, having signed an exclusive distribution agreement for “Miglow” with Global SCP in Singapore and an exclusive distribution agreement for “Silkro” with a medical aesthetics company in the United Arab Emirates (UAE).
A Hironic Co.,Ltd official stated, “We will continue to pursue a predictable and consistent shareholder return policy and create a virtuous cycle in which corporate value and shareholder value grow together through new product approvals and global market expansion.”